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Abstract
Damage to the skin initiates a cascade of well-orchestrated events that ultimately leads to repair of the wound. The
inflammatory response is key to wound healing both through preventing infection and stimulating proliferation and
remodeling of the skin. Mast cells within the tissue are one of the first immune cells to respond to trauma, and upon
activation they release pro-inflammatory molecules to initiate recruitment of leukocytes and promote a vascular response in
the tissue. Additionally, mast cells stimulate collagen synthesis by dermal fibroblasts, suggesting they may also influence
scar formation. To examine the contribution of mast cells in tissue repair, we determined the effects the mast cell inhibitor,
disodium cromoglycate (DSCG), on several parameters of dermal repair including, inflammation, re-epithelialization,
collagen fiber organization, collagen ultrastructure, scar width and wound breaking strength. Mice treated with DSCG had
significantly reduced levels of the inflammatory cytokines IL-1a, IL-1b, and CXCL1. Although DSCG treatment reduced the
production of inflammatory mediators, the rate of re-epithelialization was not affected. Compared to control, inhibition of
mast cell activity caused a significant decrease in scar width along with accelerated collagen re-organization. Despite the
reduced scar width, DSCG treatment did not affect the breaking strength of the healed tissue. Tryptase b1 exclusively
produced by mast cells was found to increase significantly in the course of wound healing. However, DSCG treatment did
not change its level in the wounds. These results indicate that blockade of mast cell activation reduces scar formation and
inflammation without further weakening the healed wound.
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Introduction
Mast cells have long been regarded primarily as effector cells in
hypersensitivity reactions. While their importance during an
allergic reaction cannot be denied, mast cells also have a
significant influence on the tissue repair process [1–3]. Mast cells
are widely distributed in the body, and are prominent near
surfaces exposed to the environment, including the skin [1]. Thus,
mast cells are one of the first cells to respond to trauma and
stimulate an immune response through the release of preformed
biological mediators. In response to wounding, mast cells
degranulate and the granule contents stimulate activation and
proliferation of endothelial cells within the tissue [1,4,5]. Cytokines
released by mast cells promote proinflammatory cytokine produc-
tion by resident cells, attracting inflammatory cells. The release of
vasoactive amines stimulates vessel permeabilization, promoting
the influx of neutrophils, macrophages and additional mast cells
into the tissue. Thus the activation and degranulation of resident
mast cells intensifies and extends the inflammatory response [1,4].
Mast cells are prominent in scar tissue, and activated mast cells
remain in the scar up to a year after wounding [6]. Mast cell
activation may influence wound remodeling as excess inflamma-
tion and cytokine production can promote scar formation [2,4,6].
Scarless healing of oral mucosal wounds in the red Duroc pig, a
common model for hypertrophic scarring, has less numbers of
mast cells compared to skin wounds [7]. Mast cells may also more
directly influence collagen synthesis. Within the dermis, activated
mast cells release mediators, including tryptase, that stimulate
fibroblasts to synthesize collagen [1,8–10]. Tryptase has also been
reported to induce the differentiation of fibroblasts into myofibro-
blasts [10]. Myofibroblasts play a fundamental role in wound
contraction, a process that reduces wound volume and speeds
closure [11]. Moreover, myofibroblast activity has been linked to
hypertrophic scarring and other fibrotic pathologies [12]. A
commercially available mast cell stabilizer, ketotofen, reduced
fibrosis and scarring in red duroc pigs [13]. In a scald injury model
of WBB6F1-kitw/kitw-v mast cell deficient mice, the dermis was
thinner and fibrous proliferation was less extensive at the wound
edge after inducing injury than in wild type mice [14]. Together,
these studies suggest that mast cells may influence scar formation.
Most previous studies of the role of mast cells in wound healing
have utilized the WBB6F1-kitw/kitw-v mast cell deficient mice [14–
16]. Due to a c-kit mutation, these mice have a nearly complete
deficiency of both mast cells and melanocytes [17,18]. However,
they also have several other abnormalities that might influence
healing outcomes, such anemia [19]. While previous studies are
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somewhat conflicting, the wounds of WBB6F1-kitw/kitw-v mice
have been described to have reduced numbers of neutrophils, yet
to exhibit minimal defects in wound closure [15].
The goal of the current study was to directly examine the role of
mast cells on scar formation in a normally healing wound. To
avoid the confounding phenotype of genetically mutant mast cell
deficient mice, we utilized a pharmacologic approach to inhibit
mast cells. DSCG inhibits calcium-induced membrane permeabil-
ity, preventing mast cell degranulation, and has an established
function in the prophylactic treatment of allergic diseases [20–22].
Using a mouse model of excisional wounds, we found that DSCG
treatment decreased scar formation and inflammation without
reducing skin strength. These data point to a distinct role for mast
cells in scar formation in skin repair, and suggest that mast cell
inhibition could improve healing outcomes.
Materials and Methods
Animals and Wound models
All animal procedures were approved by the Loyola University
and University of Illinois at Chicago Institutional Animal Care
and Use Committees. Six- to eight-week old female Balb/c mice
(Harlan, Inc, Indianapolis, IN) were anesthetized under isoflurane
(Abbott Laboratories, Abbott Park, IL) inhalation. Two dermal
wounds were placed on opposite sides of the midline at the scapula
level using a 3 mm punch biopsy instrument (Acu-Punch,
Acuderm Inc., Ft. Lauderdale, FL) as previously described [23].
At various intervals after injury, wound and surrounding tissues
were removed with a biopsy punch for analysis.
Real time PCR
Total RNA was extracted from TriZol lysates per the
manufacturer’s instruction and treated with DNase I (Invitrogen).
cDNA was prepared from total RNA using a Retroscript kit
(Invitrogen). Collagen I mRNA expression was determined by a
StepOne plus real time PCR system (Applied Biosystem, Foster
City, CA) using gene specific primers (forward: 59-
GGTATGCTTGATCTGTATCTGC-39and reverse: 59-AGTC-
CAGTTCTTCATTGCATT-39) and SYBR green mater mix
(Applied Biosystem). The relative quantity of collagen I mRNA in
tryptase b1 treated and untreated cells was determined using
22DDCt method. GAPDH was used for normalization. The
primers for GAPDH were as previously published [24].
DSCG treatment of mice
To assess the effects of mast cell degranulation on would repair;
mice were injected intraperitoneally with DSCG (Sigma) or PBS.
Thirty minutes prior to wounding, 200 ml of DSCG (160 mg/kg)
or PBS was administered as previously described [25]. Additional
doses were given at 24, 48 and 72 hours post-wounding.
Quantification of mast cells
To determine the number of mast cells within the wound bed,
individual wounds were embedded and frozen and 10 mm sections
were prepared using a cryostat. Frozen sections were thawed and
fixed for 1 hour in Carnoy’s fixative (60% ethanol, 30%
chloroform, and 10% glacial acetic acid). Sections were stained
for 2 hours at room temperature with 0.5% toluidine blue (Sigma)
in 0.5N HCl in PBS. Following dehydration and xylene clearing,
cover slips were mounted on each slide with Cytoseal (Richard-
Allan Scientific, Kalamazo, MI). Mounted sections were viewed
under a 206 objective, the wound bed was delineated, and the
number of mast cells within the center of the wound bed was
determined. The total area of the wound bed was measured using
Scion Image. Three sections per mouse were averaged. Wounds
from five mice per treatment group were counted, and mast cell
numbers were expressed as the total number of mast cells/area
(mm2) of the wound sections.
Analysis of wound re-epithelialization
The extent of re-epithelialization was measured by histomor-
phometric analysis of 5 mm tissue sections from the central portion
of the wound that had been stained with hematoxylin and eosin.
Using a standard ocular grid, the distance between the muscle
edges, and the distance that the epithelium had traveled across the
wound were measured. In order to determine the percent re-
epithelialization, the following formula was used: % Re-epithelia-
lization= (Distance covered by the epithelium/Distance between
muscle edges)6100.
Inflammatory cytokine analysis
Cytokine analysis was performed using the Bio-Rad, Bio-Plex
assay. Individual wounds were homogenized in 1 ml cell lysis
buffer (from the Cell Lysis Kit, Bio-Rad) containing 500 mM
phenylmethylsulfonyl fluoride in dimethyl sulphoxide (both from
Sigma). Tissue was further disrupted by sonication. Samples were
centrifuged and supernatants filtered through a 32 mm syringe
filter with 1.2 mm membrane (Pall Life Sciences, Cornwall, UK).
The supernatants were collected and stored at 280uC. The Bio-
Plex mouse cytokine assay for simultaneous quantitation of
interleukin (IL)-1a, IL-1b, and CXCL1 was used according to
the manufacturer’s protocol. Briefly, the premixed standards were
reconstituted in 0.5 ml cell lysis buffer, generating a stock
concentration of 50 ng/ml for each cytokine. The standard stock
was serially diluted in cell lysis buffer to generate 8 points for the
standard curve. The assay was performed in a 96-well filtration
plate supplied with the assay kit. Premixed beads (50 ml) coated
with target capture antibodies were transferred to each well of the
filter plate and washed twice with Bio-Plex wash buffer. Premixed
standards or samples (50 ml) were added to each well containing
washed beads. The plate was shaken for 30 seconds and then
incubated at room temperature for 30 minutes with low-speed
shaking. After incubation and washing, premixed detection
antibodies (50 ml) were added to each well. The incubation was
terminated after shaking for 10 minutes at room temperature.
After washing three times, the beads were resuspended in 125 ml of
Bio-Plex assay buffer. Beads were read on the Bio-Plex suspension
array system, and the data is analyzed using Bio-Plex ManagerTM
software with 5PL curve fitting. Cytokine levels in picograms were
normalized to total protein concentrations as determined by the
Bio-Rad Protein Assay (Bio-Rad).
Analysis of neutrophil myeloperoxidase (MPO)
Excisional wounds from DSCG treated and control animals
(n = 6 per group, per time point) were harvested at 1, 2, and days
post-injury, snap-frozen with liquid nitrogen and stored at 280uC
until analysis. MPO levels were determined as previously
described [26]. To prepare samples, individual wounds were
homogenized in 2.0 mL of 20 mmol/L phosphate buffer, pH 7.4.
Homogenates were centrifuged at 12,0006 g for 45 minutes, and
the supernatant was decanted. The pellets were resuspended in
1.0 mL of 50 mmol/L phosphate buffer containing 10 mmol/L
ethylenediamine tetraacetic acid and 0.5% hexadecyltrimethylam-
monium bromide. After a freeze-thaw cycle, the samples were
sonicated briefly and incubated a 60uC for 2 hour to release
maximal MPO activity. The samples were centrifuged at 500 g for
10 minutes and the supernatant was transferred to 1.5 mL tubes
for storage at 220uC.
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For analysis, samples were thawed and MPO standard (Sigma)
was diluted to generate a standard curve ranging from 0 to 3.0
units per mL. Then 12.5 mL aliquots of sample or standard were
placed in 96-well tissue culture plates with 125 mL of assay buffer
(0.1 mol/L phosphate buffer, pH 5.4, 1% hexadecyltrimethylam-
monium bromide, 0.43 mg per mL 3, 39, 5, 59- tetramethylbenzi-
dine). The reactions were started by the addition of 12.5 mL of
15 mmol/L H2O2, incubated at 37uC for 15 minutes, and stopped
with 250 mL cold 0.2 mol/L sodium acetate, pH 3.0. The
absorbance of each sample was determined by reading absorbance
at 655 nm within 10 minutes.
Histological assessment of collagen content and
architecture of scars
Wound samples from DSCG or PBS treated mice were
harvested 14 and 21 days post-wounding. Skin samples were
embedded in paraffin and 5 mm sections were cut, mounted on
slides and stained with hematoxylin to verify a central wound
location. To determine changes in the orientation of collagen
fibers, tissue sections from DSCG or PBS treated mice were
analyzed by picrosirius red staining (Sigma). Deparaffinized
sections were hydrated, then sections were stained with a 0.01%
solution of Sirius red F3BA in saturated aqueous picric acid
(Electron Microscopy Sciences, Hatfield, PA) for 90 minutes. After
staining, slides were washed for two minutes in 0.01 N HCl, rinsed
for one minute in 80% ethanol, dehydrated, cleared and cover
slips were mounted in Permount (Fisher, Fairlawn, NJ). The
sections were examined under polarized light with a Zeiss
AxioVert 200 microscope and images were captured at 206
magnification.
Transmission electron microscopy (TEM)
For ultrastructural collagen analysis, normal skin and wound
tissues were fixed in 4% glutaraldehyde. After rinsing with
0.1 mol/L sodium cacodylate buffer, samples were post-fixed in
1% osmium tetraxide, dehydrated in graded alcohols, and
embedded in Spurr’s epoxy resin (Electron Microscopy Sciences,
Fort Washington, PA). Ultrathin sections (80 nm) were collected
on grids, stained with uracyl acetate and lead citrate and examined
using a Hitachi H-600 (75 kV) TEM as previously described [26].
The wound bed was identified using a serial section stained with
toluidine blue. TEM images of collagen fibril cross-sections were
taken at random within the boundaries of the wound bed at a
magnification of 30,0006 and the photographic negatives were
scanned into Adobe Photoshop. The diameter of the collagen
fibrils was measured using Scion Image. Five normal skin samples
and five wound samples from each time point, all from different
mice, were used for analysis. Each electron micrograph was
divided into four parts for analysis, and fibrils from four
micrographs per sample were measured. A total of 1100–2100
fibrils per animal were analyzed [26]. Images of fibroblasts within
the wound bed were captured at 80006and the photographs were
scanned into Adobe Photoshop (Adobe Systems Incorporated, San
Jose, CA).
Measurement of fibril Density
The mean fibril density was determined by image analysis of
TEM sections of wounds from either DSCG or PBS treated mice.
Sections were analyzed by Scion Image software (Scion Corp.,
Frederick, MD). The area of each micrograph was determined
using a freehand drawing tool. Each fibril was identified and the
total area occupied by fibrils in each micrograph was counted
using a colorization tool. Fibril density is expressed as the percent
of total area occupied by fibrils from ten micrographs per mouse.
At each time point, the percent area density was determined for
ten micrographs from each of five mice.
Measurement of scar width
Paraffin sections from the center of the wound bed were stained
with Masson’s trichrome stain (Sigma) as described [27]. The
tissue was visualized using a Zeiss AxioVert 200 microscope and
scar width was measured with a stage micrometer. The average
scar width from three sections per mouse was calculated and a
total of five mice per group were analyzed.
Wound breaking strength
Under anesthesia, a 4 cm full thickness skin incision was made
on the shaved backs of mice treated with PBS or DSCG. The
incisions were closed with surgical clips, which were removed on
the fifth post-operative day. On day 14 after surgery, animals were
euthanized and three skin strips perpendicular to the incision per
mouse were cut. These strips were subjected to tensiometry using a
materials testing system, designed and built by the Department of
Surgery and Instrument Models Facility at the University of
Vermont [28]. Wound disruption strength was defined as the load
required to break the wound along the incision and is represented
in grams.
Western Blot tryptase b1 analysis
To examine the protein levels of tryptase b1 in the wound
tissues, normal skin tissues and wound samples were homogenized
in RIPA buffer (Sigma) with protease inhibitors (Sigma). Samples
were centrifuged at 13000 rpm at 4uC for 15 minutes, and protein
concentration determined for the resulting supernatants. 150–
180 mg mg of each protein sample was loaded onto a 10% Tris-
glycine acrylamide gel (Bio-Rad). Separated proteins were
transferred to a nitrocellulose membrane and first blocked with
5% skim milk in Tris buffered saline. Membranes were exposed to
goat anti-mouse tryptase b1 at 0.2 mg/ml (R&D systems Minne-
apolis, MN) and a rabbit anti-human a-tubulin (Abcam, Cam-
Figure 1. Quantitation of mast cell numbers after DSCG
treatment. Total mast cells numbers were counted using toluidine
blue staining of tissue sections from cutaneous wounds (squares) or
wounds from animals treated with DSCG (triangles). The total number
of mast cells were counted per wound, followed by measurement of
total wound area. Three sections per mouse were averaged. Data is
represented as total mast cells per area of the wound (n = 5). *p,0.05
compared to PBS group,#p,0.01 compared to 0 hour in PBS group by
t-test.
doi:10.1371/journal.pone.0085226.g001
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bridge, MA) at 1/3000 dilution which cross reacts with mouse a-
tubulin for 1 hour at room temperature. The membrane was
washed and then incubated with rabbit anti-goat and goat anti-
rabbit HRP (Bio-Rad) at 1/2500 dilution. The membrane was
developed using an ECL system (Piscataway, NJ). Imaging of the
resulting membrane was performed and analyzed using a
ChemiDoc system (Bio-Rad).
Fibroblast cell culture
To investigate the effects of tryptase b1 on collagen I gene
expression and the differentiation of dermal fibroblasts to
myofibroblasts, dermal fibroblasts were isolated from mouse dorsal
skin. To isolate fibroblasts, skin was first shaved and excised, and
then the tissues were spread dermis side down in a sterile tissue
culture dish and incubated overnight with 0.1% dispase at 4uC.
Following removal of the epidermis, the dermis was cut into small
pieces and incubated with 0.5% collagenase type I (Sigma) in
DMEM at 37uC for 2 h, then dissociated into a cellular
suspension. Cells were washed twice to remove collagenase then
cultured in DMEM with 10% fetal bovine serum (FBS). The cells
were incubated until 60–70% confluent and the medium was
changed to DMEM without FBS for 24 hours. Cultures were
treated with mouse recombinant tryptase b1 (R&D systems) at
1 mg/ml in the presence of the same concentration of heparin as a
stabilizer of tryptase b1 [8]. Control cultures were treated with
heparin only. At 24 and 48 hours, cells were harvested using
TriZol for real time PCR analysis. At 72 hours, cells were fixed
with acetone for 15 minutes and then subjected to immunofluo-
rescent staining as described below.
a-smooth muscle actin (SMA) immunofluorescent
detection
Acetone fixed fibroblasts on chamber slides were incubated with
10% normal mouse serum for 45 minutes followed by FITC
conjugated mouse monoclonal anti-a-SMA (Sigma) for 1 hour at
room temperature. After washing, the slides were mounted with
50% glycerol in PBS, and then observed using a Zeiss AxioVert
200 fluorescence microscope. DAPI was used for nuclear staining.
The images were recorded by an attached digital camera. 200 cells
were counted in each slide, and the percent of a-SMA positively
stained cells was calculated.
Statistical analysis
Data were analyzed using GraphPad Prism (GraphPad Soft-
ware, Inc., San Diego, CA). The mean and SEM were calculated
for each data set. A two-way analysis of variance (ANOVA)
followed by a Bonferroi post-test or t-test was performed. For
studies with two groups, a t-test was used. For all analyses, values
of p,0.05 were considered statistically significant.
Results
DSCG inhibits mast cell activation in wounds
The mast cell inhibitor, DSCG was used to assess the effects of
mast cell activation on wound healing. To verify inhibition of mast
cell activation after DSCG treatment, toluidine blue was used to
stain mast cell granules. Fig. 1 shows that unwounded tissue from
mice treated with DSCG and PBS contained similar numbers of
mast cells. Upon wounding, the number of mast cells in PBS
Figure 2. Microscopic assessment of scar tissue by Picrosirius
Red staining. Sections of scar tissue from either DSCG treated mice or
PBS treated mice at day 21 post-wounding were stained with picrosirius
red and viewed under polarized light to detect collagen fibers. Mature
collagen fibers appear red-orange and immature collagen fibers appear
yellow and green. Results are representative to three independent
experiments. Dot line framed areas are wounds.
doi:10.1371/journal.pone.0085226.g002
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treated wounds decreased significantly by 12 hours (p,0.01), most
likely representing massive degranulation. In contrast, the number
of mast cells in DSCG treated wounds did not decrease compared
to levels in normal tissues. Levels of visible mast cells in wounds of
DSCG mice were significantly more than that in PBS treated
wounds (p,0.05), again likely representing a relative decrease in
degranulation due to DSCG treatment. In control mice, activation
and loss of visible mast cells was followed by restoration of mast
cells above baseline levels by 24 hours post-wounding (p,0.05),
likely representative of an influx of mast cells in response to
localized mast cell activation (Fig. 1). In contrast, mast cells from
wounds in mice injected with DSCG treatment remained
granulated. These data confirm that DSCG inhibits mast cell
degranulation in our model system.
DSCG treatment leads to improved collagen fiber
organization in wounds
The ultimate result of the repair process in adults is a scar,
marked by an overproduction of disorganized collagen patching
the break in the tissue. To determine the role of mast cell
activation on collagen organization after wound healing, wounds
from mice treated with DSCG or PBS were examined by
picrosirius red staining at day 21 post-wounding and examined
under polarized light. In normal skin, collagen is arranged in
organized bundles that appear as brightly birefringent structures
throughout the whole microscopic field. When collagen fibers are
not regularly arranged, they are weakly birefringent [29].
Examination of picrosirius red stained sections of normal
unwounded skin showed a dermal architecture characterized by
collagen fibers with a red-orange birefringence organized in a
basket weave pattern (Fig. 2a). Collagen fibers in scar tissue from
mice treated with DSCG had a predominantly red-orange
birefringence and were oriented in a more orderly fashion, similar
to normal tissue architecture (Fig. 2b). Analysis of scar tissue from
PBS-treated mice demonstrated that collagen fibers were charac-
terized by thin, weakly birefringent yellow-green fibers with
irregular collagen organization and poorly defined structure
(Fig. 2c).
Figure 3. Ultrastructural analysis of collagen fibril content. (a) Transmission Electron Microscopy of normal skin and the tongue. n = 5 for all
groups. TEM was performed to examine collagen fibril structure in the dermis of control mice (upper panels) and mice treated with DSCG (lower
panels). (b). The diameter of individual collagen fibrils was determined for between 1100 and 2100 fibrils per section. Two separate wound sections
per mouse were examined and four micrographs per mouse were analyzed. The mean fibril diameter per mouse was calculated. The average collagen
diameter (n = 5) at each time point is shown. (c). Measurement of fibrillar density after DSCG treatment. The mean area density was determined by
image analysis of TEM sections of wounds from either DSCG or PBS treated mice. The average area density was calculated from 10 micrographs per
mouse. Data are expressed as mean 6 SEM (n= 5). *p,0.01 by t-test.
doi:10.1371/journal.pone.0085226.g003
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DSCG treatment yields increased collagen fibrillar density
in wounds
The results from the picrosirius red staining indicated that
treatment with DSCG prior to wounding resulted in tissue similar
to normal skin. To analyze the architecture of the skin in mice
treated with DSCG compared to control mice, we used TEM to
measure the diameter of fibrils in scar tissue at 7, 14 and 21 days
post-wounding. Changes in the homogeneity of fibril diameter
correlate to fibrosis and scarring. The representative photographs
in Fig. 3a show that compared to unwounded skin, both treatment
groups show an increase in small diameter fibrils, suggesting scar
formation. However, there was no significant difference in the
distribution of fibril diameter (Fig. 3b). While the fibril diameter
was unchanged, fibril density was influenced by inhibition of mast
cells. Comparison of fibril density between the two treatment
groups revealed that wounds from DSCG treated mice exhibited a
much higher fibrillar density (Fig. 3c).
DSCG treatment causes a reduction in wound scar width
Another measurement of healing capability is the assessment
scar width. To determine if DSCG treatment and decreased mast
cell degranulation influenced scar width, we measured the width of
wound sections from both PBS and DSCG treated animals. Scar
width was significantly reduced in mice treated with DSCG,
suggesting that blockade of mast cell activation reduces cutaneous
scarring (Fig. 4a).
DSCG treatment does not affect wound breaking
strength
The success of dermal healing can be measured by assessing the
ability of healing skin to withstand tensile forces. To determine if
wounds from DSCG treated mice were equally strong as control
wounds, we measured wound breaking strength. As shown in
Fig. 4b, there was no significant difference in wound breaking
strength in mice treated with DSCG compared to mice treated
with PBS. These results suggest that while DSCG does reduce
scarring, this treatment does not decrease the strength of the
healed skin.
DSCG treatment causes decreased wound inflammation
The granules stored within mast cells contain a multitude of
preformed inflammatory mediators. Upon activation, the granules
are released into the surrounding tissue, leading to the initiation if
inflammation. To determine if the prevention of mast cell
degranulation alters the inflammatory response, levels of IL-1a,
IL-1b and CXCL1 were measured at 3,6, 12 and 24 hours post-
wounding. Levels of IL-1a in unwounded skin were similar in both
treatment groups. In mice treated with PBS, IL-a production
peaked at 6 hours post-wounding and gradually decreased, while
levels of IL-1a in mice treated with DSCG were significantly
decreased at 3,6 and 12 hours post-wounding (Fig. 5a). Levels of
IL-1b in unwounded skin of both groups were similar. While both
groups showed a peak of IL-1b production at 6 hours post-
wounding, there was a significant decrease in the IL-b production
in wounds of mice treated with DSCG (Fig. 5b). Similarly,
CXCL1 (murine IL-8) levels peaked by 12 hours in both groups,
but CXCL1 production was significantly decreased in mice treated
with DSCG at 6, 12 and 24 hours post-wounding (Fig. 5c). These
data are consistent with the idea that mast cell degranulation
initiates the production and secretion of early inflammatory
cytokines and further demonstrate the efficacy of DSCG treatment
decreasing inflammation in response to wounding.
The reduction in early inflammatory cytokines in wounds from
DSCG treated mice suggested that inflammatory cell recruitment
might also be affected by reducing mast cell activation. To
determine if reduction in inflammatory cytokines after DSCG
treatment reduced neutrophil infiltration, wounds were subjected
to MPO analysis. MPO activity in DSCG treated mice was
significantly decreased in response to injury (Fig. 5d) especially at
day 1 after treatment (p,0.05).
DSCG treatment does not affect wound re-
epithelialization
To determine if mast cell inhibition affects wound closure, the
rate of re-epithelialization was measured at days 3, 5 and 7 days
post-wounding in DSCG and control mice. DSCG treatment had
no effect on the process of wound re-epithelialization. Wound
closure occurred at a similar rate in mice treated with DSCG and
PBS (Fig. 6).
Figure 4. Effect of mast cell inhibition with DSCG on scar width
and wound breaking strength. (a) Average scar width in mice
treated with DSCG compared to PBS treated mice. H & E staining was
used to measure scar with at 7, 14 and 21 days post-wounding in DSCG
treated mice (black bars) and control mice (white bars). N = 5. *p,0.05.
(b) Effect of DSCG treatment on wound breaking strength. Incisional
wounds were prepared on the back of mice treated with DSCG (black
bar) or PBS (white bar). N = 10 for both groups. Wounds were excised at
day 14, and two skin strips per mouse were used from the upper and
lower back of the mouse. Both strips were subjected to tensiometric
analysis. The bars indicate the means of wound breaking strength in
grams.
doi:10.1371/journal.pone.0085226.g004
Mast Cells and Dermal Repair
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Tryptase b1 promotes differentiation of fibroblasts to
myofibroblasts and induces collagen I mRNA expression
Previous studies have demonstrated an association of mast cells
with scar formation and fibrosis, conditions typified by the
presence of myofibroblasts. To examine whether mast cell tryptase
might influence fibroblast function, we treated fibroblasts with
tryptase and examined them for the production of a-SMA, a
marker of myofibroblasts. Tryptase b1 induced 6.5+1.2% and
15.5+3.9% of dermal fibroblasts to become a-SMA positive
myofibroblasts at 24 and 48 hours after treatment respectively
(Fig. 7a&b). No a-SMA positive cells were observed in control
cultures not treated with tryptase b1 at either time point (Fig. 7a).
Furthermore, dermal fibroblasts expressed significantly more
collagen I mRNA after being treated by tryptase b1. When
compared to control, levels of collagen I mRNA were 11 fold
higher in treated cells after 48 hours of exposure to tryptase,
(Fig. 7c). These results are consistent with previous reports using
human fibroblasts [8–10,30].
Levels of mast cell derived tryptase increase in healing
wounds
An analysis of the microarray database from murine wounds
demonstrated that tryptase b1 transcript is significantly upregu-
lated in the healing wound [31]. Levels of tryptase b1 gene
expression started to increase at 6 hours after wounding and
reached peak levels at 24 hours after injury (Fig. 8a). Interestingly,
a high level of expression was sustained from 24 hours to 10 days
after wounding (Fig. 8a). Immunoblot analysis of wound lysates
demonstrated that the protein levels of tryptase b1 in wounds
(Fig. 8b&c) showed a similar pattern to the gene expression levels
(Fig. 8a). However, there were no significant changes observed in
tryptase b1 levels between the wounds of DSCG treated and
control mice (Fig. 8b&c).
Figure 5. Effect of inhibition of mast cells with DSCG on wound cytokine and neutrophil MPO levels. (a) IL-1a, (b) IL-1b, (c) CXCL1
protein levels, and (d) MPO activity were measured by ELISA in wound homogenates d from mice treated with DSCG or PBS. Results are expressed as
the mean 6 SEM (n= 3). * p,0.05 ** p,0.01 by 2-way ANOVA followed by a Bonferroni post-test.
doi:10.1371/journal.pone.0085226.g005
Figure 6. Re-epithelialization of wounds in DSCG treated mice.
The rate of re-epithelialization was measured by histomorphometric
analysis of tissue sections from the central portion of the wound.
doi:10.1371/journal.pone.0085226.g006
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Discussion
In the present study, we show that the inhibition of mast cell
degranulation during early wound repair reduces later scar
formation without disrupting wound breaking strength. Moreover,
the data demonstrate that DSCG treatment reduces the immedi-
ate inflammatory response in wounds.
Given that the inflammatory phase of wound healing promotes
downstream healing processes and that the amount of inflamma-
tion can affect the remodeling phase, we speculated that mast cell
blockade could alter scar formation. Two recent studies have
examined the epidermal components of wound healing using the
WBB6F1-kitw/kitw-v mice. While Egozi et al found no changes in
re-epithelialization in mast cell deficient mice [15], Weller et al
observed an initial change in re-epithelialization that reached
normal levels by day 10 post-wounding [32]. Mast cell reconsti-
tution alleviated the early differences, but did not increase re-
epithelialization beyond control animals. The authors suggested
that the initial enhanced re-epithelialization could be due to the
absence of histamine stored within mast cells which could promote
cutaneous repair acting as a keratinocyte mitogen [32]. While both
of these studies suggest a role for mast cells using the kitw/kitw-v
mouse, these mice have other deficiencies such as minor
alterations in immune cell generation in addition to anemia, both
of which could alter the wound healing response [17,18].
Therefore, we used a pharmacological approach to inhibit mast
cell degranulation.
The predominant step in the sequence of biochemical events
following immunological stimulus of mast cells is a transient
increase in the permeability of the plasma membrane to calcium
ions [20,22,33]. DSCG inhibits mast cell degranulation and has an
established function in the prophylactic treatment of allergic
diseases [25,34]. Although the precise molecular mechanism of
inhibition is unknown, studies have shown that DSCG bind s
specifically to the external membranes of mast cells and basophils
in a calcium-dependent fashion. Binding of these channels is
believed to stabilize mast cell granules, prevention degranulation
[25,34]. These studies suggest that inhibitory effects of DSCG on
mast cell make it an interesting candidate for the treatment of
wounds.
Previous studies by us and others that utilized the WBB6F1-
kitw/kitw-v mice were limited to the inflammatory and proliferative
stages of wound healing, but did not examine scar formation.
Since DSCG treatment did not change the rate of wound re-
epithelialization, we performed additional analysis of the later
remodeling and scar formation aspects of repair. These studies
revealed that inhibition of mast cell degranulation with DSCG
resulted in a wound bed with more organized collagen, and with
architecture more similar to normal skin. An ultrastructural level
analysis of fibril diameter showed that mast cell inhibition did not
seem to impact this parameter. However, the fibrillar density in
wounds of mice subjected to DSCG was much greater than those
of control mice. Despite the increase in fibrillar density, DSCG
treatment did not improve wound breaking strength. This may not
be surprising as multiple studies suggest that it is a challenge to
improve wound breaking strength of normal animals.
Of great interest was the finding that the inhibition of mast cells
led to a significantly reduced scar width. This finding suggests an
important effect of mast cells in wound healing and scar
development that might be eventually exploited to improve
healing outcomes. Our results suggest that this effect may involve
both direct and indirect mechanisms. The indirect mechanism
may derive from the reduction in wound inflammation that was
seen following the inhibition of mast cells.
In our current study, the number of mast cells in 12 hour-
wounds was significantly decreased in the PBS control group but
remained steady in DSCG treated mice. The reasons for this
decrease might be massive degranulation, apoptotic death and/or
migration away from the wounds. However, previous studies
demonstrate that DSCG had strong inhibitory effect of mast cell
degranulation [25,34]. Therefore, it seems very likely that the
steady levels of mast cells in the wounds of DSCG treated animals
result from the inhibition of degranulation.
Figure 7. Tryptase b1 induces a-SMA and collagen I expression in dermal fibroblasts. (a). Tryptase b1 induces differentiation of dermal
fibroblasts into myofibroblasts. Dermal fibroblasts were treated with tryptase b1 for 72 hours and a-SMA expression was detected using direct
immunofluorescence. Green stained cells are a-SMA positive myofibroblasts. DAPI was used to counterstain nuclei (blue). (b). Percent of a-SMA
positive myofibroblasts. ND: not detectable. (c). Relative mRNA expression of collagen I 24 hours after tryptase b1 treatment determined by real time
PCR. Results were the averages of triplicate wells.
doi:10.1371/journal.pone.0085226.g007
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A correlation between inflammation and fibrosis in response to
wound healing has been clearly demonstrated in the fetal wound
model and further supported by our own studies of reduced
scaring during mucosal healing [23,27,35]. Of the many factors
that contribute to privileged healing, a decreased inflammatory
response appears to be very important. A direct mechanism for
mast cell influence on scar formation was suggested by our studies
of mast cell tryptase. Our results demonstrate that tryptase levels
are high in wounds for an extended period of time. Similar to
studies in other systems, we found that tryptase can induce murine
fibroblasts to adopt the myofibroblast phenotype. Together, these
data suggest that mast cell tryptase may affect scar formation.
Thus, the reduction in scar formation in DSCG treated mice may
be due to the fact that this drug inhibits mast cell degranuation
and extracellular release of tryptase.
To assess whether DSCG treatment does in fact reduce active
tryptase levels, we performed immunoblot analysis of tryptase
within wounds of DSCG mice. Interestingly, this experiment
demonstrated that the levels of tryptase in wounds of DSCG
treated mice were not significantly different than control. In
considering this result, we realized that this negative finding is
most probably due to the fact that Western blot, the assay used in
current study, cannot distinguish between free tryptase that is
released by mast cells and tryptase localized within mast cells.
Because DSCG does not delete but only stabilizes mast cells,
tryptase remains in the cells and is detectable, although not active
in the wounds of DSCG treated mice.
We do not know if DSCG has any direct effects on the
recruitment or functions of neutrophils. In our study we found that
MPO levels were significantly reduced in the DSCG treated
wounds (24 hours), which is consistent with recent studies that
observed DSCG treatment could decrease the influx of neutrophils
in bronchoalveolar lavage fluid or peritoneal cavity [36].
One aspect of wound repair that was not investigated in the
current study is the influence of DSCG treatment on wound
angiogenesis. Mast cells produce proangiogenic mediators such as
fibroblast growth factor-2 and vascular endothelial cell growth
factor (VEGF) [14,37,38], suggesting that mast cells may play a
role in angiogenesis. However, a previous study from our lab
demonstrated that that wounds of WBB6F1-kitw/kitw-v mast cell
deficient and control mice have similar blood vessel content and
VEGF levels [15]. Although the current study employs a different
method of interfering with mast cell function, our prior result in
the WBB6F1-kitw/kitwv mast cell deficient mice suggests that
DSCG treatment would not alter wound angiogenesis.
The experiments presented here provide evidence that the mast
cell, once thought to only play a role in allergic responses, could be
a key component of inflammatory initiation in response to wound
healing. The concept that inhibition of mast cells during wound
healing leads to more organized collagen architecture and smaller
scars without disruption of wound integrity implicates mast cells as
a therapeutic target. This could be especially true in conditions
characterized by excess scarring. Further understanding of the
mechanism of reduced scar formation as a result of mast cell
inhibition may allow the development of applications to promote
optimal wound healing.
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